[A20-59] Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Last updated 15.10.2020
Project no.:
A20-59
Commission:
Commission awarded on 15.07.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Indication:
| Adults with relapsing remitting multiple sclerosis (RRMS) |
Result of dossier assessment:
| Treatment-naive patients or patients whose RRMS is not highly active under disease-modifying therapy: proof of considerable added benefit. Highly active RRMS despite therapy: proof of non-quantifiable (at least considerable) added benefit for men; for women: added benefit not proven. |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the decides of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A20-96 | Ozanimod (multiple sclerosis) - Addendum to Commission A20-59 | Commission completed |
| A21-166 | Ozanimod (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
07.01.2021 A G-BA decision was published.